Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Reury-Perng Perng

Showing results (41-50 of 91) with videos related to

Pageof 10
Sort By:
Lung|September 29, 2006
Inhaled fluticasone and salmeterol suppress eosinophilic airway inflammation in chronic obstructive pulmonary disease: relations with lung function and bronchodilator reversibilityDiahn-Warng Perng, Cheng-Che Wu, Kang-Cheng Su, et al.
Lung Cancer (Amsterdam, Netherlands)|September 26, 2006
Gefitinib as front-line treatment in Chinese patients with advanced non-small-cell lung cancerWei-Chun Lin, Chao-Hua Chiu, Jia-Ling Liou, et al.
American Journal of Clinical Oncology|October 24, 2002
Phase II study of docetaxel and gemcitabine combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapyYuh-Min Chen, Reury-Perng Perng, Wei-Chun Lin, et al.
Lung Cancer (Amsterdam, Netherlands)|December 18, 2004
Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicityChao-Hua Chiu, Chun-Ming Tsai, Yuh-Min Chen, et al.
Journal of the Chinese Medical Association : JCMA|March 4, 2005
Clinical features and outcomes of severe acute respiratory syndrome and predictive factors for acute respiratory distress syndromeCheng-Yu Chen, Chen-Hsen Lee, Cheng-Yi Liu, et al.
Lung Cancer (Amsterdam, Netherlands)|April 24, 2007
Serum tumor markers as predictors for survival in advanced non-small cell lung cancer patients treated with gefitinibChao-Hua Chiu, Yu-Ning Shih, Chun-Ming Tsai, et al.
Cancer|March 14, 2007
Phase II randomized study of daily gefitinib treatment alone or with vinorelbine every 2 weeks in patients with adenocarcinoma of the lung who failed at least 2 regimens of chemotherapyYuh-Min Chen, Jacqueline Ming Liu, Teh-Ying Chou, et al.
Cancer Biomarkers : Section a of Disease Markers|October 21, 2015
A prospective study of the use of circulating markers as predictors for epidermal growth factor receptor-tyrosine kinase inhibitor treatment in pulmonary adenocarcinomaYung-Hung Luo, Pei-Chun Tseng, Yu-Chin Lee, et al.
Cellular Signalling|December 5, 2002
Involvement of phosphatidylinositol 3-kinase gamma in neutrophil apoptosisKuang-Yao Yang, John Arcaroli, John Kupfner, et al.
Japanese Journal of Clinical Oncology|November 24, 2005
Phase II randomized trial of tri-weekly versus days 1 and 8 weekly docetaxel as a second-line treatment of advanced non-small cell lung cancerChun-Liang Lai, Chun-Ming Tsai, Chao-Hua Chiu, et al.
Pageof 10

Showing results (41-50 of 91) with videos related to

Sort By:
Pageof 10
Lung|September 29, 2006
Inhaled fluticasone and salmeterol suppress eosinophilic airway inflammation in chronic obstructive pulmonary disease: relations with lung function and bronchodilator reversibilityDiahn-Warng Perng, Cheng-Che Wu, Kang-Cheng Su, et al.
Lung Cancer (Amsterdam, Netherlands)|September 26, 2006
Gefitinib as front-line treatment in Chinese patients with advanced non-small-cell lung cancerWei-Chun Lin, Chao-Hua Chiu, Jia-Ling Liou, et al.
American Journal of Clinical Oncology|October 24, 2002
Phase II study of docetaxel and gemcitabine combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapyYuh-Min Chen, Reury-Perng Perng, Wei-Chun Lin, et al.
Lung Cancer (Amsterdam, Netherlands)|December 18, 2004
Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicityChao-Hua Chiu, Chun-Ming Tsai, Yuh-Min Chen, et al.
Journal of the Chinese Medical Association : JCMA|March 4, 2005
Clinical features and outcomes of severe acute respiratory syndrome and predictive factors for acute respiratory distress syndromeCheng-Yu Chen, Chen-Hsen Lee, Cheng-Yi Liu, et al.
Lung Cancer (Amsterdam, Netherlands)|April 24, 2007
Serum tumor markers as predictors for survival in advanced non-small cell lung cancer patients treated with gefitinibChao-Hua Chiu, Yu-Ning Shih, Chun-Ming Tsai, et al.
Cancer|March 14, 2007
Phase II randomized study of daily gefitinib treatment alone or with vinorelbine every 2 weeks in patients with adenocarcinoma of the lung who failed at least 2 regimens of chemotherapyYuh-Min Chen, Jacqueline Ming Liu, Teh-Ying Chou, et al.
Cancer Biomarkers : Section a of Disease Markers|October 21, 2015
A prospective study of the use of circulating markers as predictors for epidermal growth factor receptor-tyrosine kinase inhibitor treatment in pulmonary adenocarcinomaYung-Hung Luo, Pei-Chun Tseng, Yu-Chin Lee, et al.
Cellular Signalling|December 5, 2002
Involvement of phosphatidylinositol 3-kinase gamma in neutrophil apoptosisKuang-Yao Yang, John Arcaroli, John Kupfner, et al.
Japanese Journal of Clinical Oncology|November 24, 2005
Phase II randomized trial of tri-weekly versus days 1 and 8 weekly docetaxel as a second-line treatment of advanced non-small cell lung cancerChun-Liang Lai, Chun-Ming Tsai, Chao-Hua Chiu, et al.
Pageof 10